| sinespace

Oc Biol 2005, 78:1192?197. Romero-Sandoval EA, Horvath R, Landry RP, DeLeo JA: Cannabinoid

Revision as of 09:54, 25 April 2019 by Chime77gold (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D, Tuma RF: Modulation of cannabinoid receptor Ic retinopathy [28. In addition, the probability of regression curves according to decrease] Activation as a neuroprotective strategy for EAE and stroke. Li GZ, Zhang Y, Zhao JB, Wu GJ, Su XF, Hang CH: Expression of myeloid differentiation major response protein 88 (Myd88) in the cerebral cortex following experimental traumatic brain injury in rats. Brain Res 2011, 1396:96?04. Giambelluca MS, Rollet-Labelle E, Bertheau-Mailhot G, PubMed ID: Laflamme C, Pouliot M: Post-transcriptional regulation of tumor necrosis factor alpha biosynthesis: relevance to pathophysiology of rheumatoid arthritis. OA.Oc Biol 2005, 78:1192?197. Romero-Sandoval EA, Horvath R, Landry RP, DeLeo JA: Cannabinoid receptor variety 2 activation induces a microglial anti-inflammatory phenotype and reduces migration by way of MKP induction and ERK dephosphorylation. Mol Discomfort 2009, 5:25. Gentleman SM, Leclercq PD, Moyes L, Graham DI, Smith C, Griffin WS, Nicoll JA: Long-term intracerebral inflammatory response right after traumatic brain injury. Forensic Sci Int 2004, 146:97?04. Loane DJ, Byrnes KR: Function of microglia in neurotrauma. Neurotherapeutics 2010, 7:366?77. Norden DM, Godbout JP: Assessment: microglia from the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol 2013, 39:19?four. Lighthall JW: Controlled cortical effect: a new experimental brain injury model. J Neurotrauma 1988, five:1?five. Elliott MB, Oshinsky ML, Amenta PS, Awe OO, Jallo JI: Nociceptive neuropeptide increases and periorbital allodynia inside a model of traumatic brain injury. Headache 2012, 52:966?84. Wiley JL, Beletskaya ID, Ng EW, Dai Z, Crocker PJ, Mahadevan A, Razdan PubMed ID: RK, Martin BR: Resorcinol derivatives: a novel template for the improvement of cannabinoid CB(1)/CB(2) and CB(two)-selective agonists. J Pharmacol Exp Ther 2002, 301:679?89. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D, Tuma RF: Modulation of cannabinoid receptor activation as a neuroprotective technique for EAE and stroke. J Neuroimmune Pharmacol 2009, four:249?59. Phares TW, Kean RB, Mikheeva T, Hooper DC: Regional differences in blood-brain barrier permeability modifications and inflammation in the apathogenic clearance of virus in the central nervous method. J Immunol 2006, 176:7666?675. Pertwee RG: Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 2010, 17:1360?381. Fishbein-Kaminietsky M, Gafni M, Sarne Y: Ultralow doses of cannabinoid drugs defend the mouse brain from inflammation-induced cognitive damage. J Neurosci Res 2014, 92:1669?677. Ashton JC, Glass M: The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 2007, five:73?0. Ramirez SH, Hasko J, Skuba A, Fan S, Dykstra H, McCormick R, Reichenbach N, Krizbai I, Mahadevan A, Zhang M, Tuma R, Son YJ, Persidsky Y: Activation of cannabinoid receptor two attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction beneath inflammatory situations. J Neurosci 2012, 32:4004?016. Reglero-Real N, Marcos-Ramiro B, Millan J: Endothelial membrane reorganization throughout leukocyte extravasation. Cell Mol Life Sci 2012, 69:3079?099. Harting MT, Jimenez F, Adams SD, Mercer DW, Cox CS Jr: Acute, regional inflammatory response soon after traumatic brain injury: implications for cellular therapy.